Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin sensitizers.

Farhad Zangeneh1, Yogish C Kudva, Ananda Basu

  • 1Division of Endocrinology, Diabetes, Metabolism, Nutrition and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.

Mayo Clinic Proceedings
|April 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular, Renal, and Hepatic Biomarkers Outside Guideline-Recommended Thresholds: Prevalence and Determinants in Type 1 Diabetes.

Diabetes technology & therapeutics·2026
Same author

Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.

Diabetes, obesity & metabolism·2026
Same author

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.

Diabetes technology & therapeutics·2026
Same author

Plasma biomarkers of neurodegeneration and intraindividual cognitive variability: Comparing variability across test at one time point and using repeated ecological momentary assessment.

Neuropsychology·2026
Same author

Plasma biomarkers of neurodegeneration and their associations with type 1 diabetes characteristics and glycemia.

Diabetes research and clinical practice·2026
Same author

Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
Same journal

In Reply: Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Long-Term Cardiovascular Burden After Carotid Endarterectomy: Moving Beyond Conventional Risk Profiling.

Mayo Clinic proceedings·2026
Same journal

Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.

Mayo Clinic proceedings·2026
See all related articles

Newer diabetes medications called insulin sensitizers improve blood sugar control and may benefit lipid metabolism and vascular health. They offer a way to address insulin resistance in type 2 diabetes.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is a growing global health issue characterized by metabolic dysregulation.
  • Insulin resistance is a central feature of T2DM and related metabolic conditions.
  • Traditional T2DM treatments included sulfonylureas and insulin, with limited options before the mid-1990s.

Purpose of the Study:

  • To review the role of insulin sensitizers in managing type 2 diabetes.
  • To discuss the impact of these agents on glycemic control, lipid metabolism, and vascular health.
  • To explore safety considerations and potential applications in diabetes prevention and related disorders like polycystic ovary syndrome.

Main Methods:

  • Literature review of therapeutic interventions for type 2 diabetes.

Related Experiment Videos

  • Analysis of evidence on insulin sensitizers, including metformin and thiazolidinediones.
  • Discussion of clinical data regarding efficacy, safety, and broader metabolic effects.

    • Main Results:

    • Insulin sensitizers effectively improve glycemic control in type 2 diabetes.
    • These agents demonstrate beneficial effects on lipid profiles and atherosclerotic processes.
    • Evidence suggests potential for preventing diabetes onset and managing related conditions.

    Conclusions:

    • Insulin sensitizers represent a significant advancement in type 2 diabetes management.
    • Their multifaceted benefits extend beyond glycemic control to cardiovascular and metabolic health.
    • Further research and clinical application are warranted for optimizing their use in T2DM and associated conditions.